Navigation Links
ChemoCentryx Initiates Clinical Trial of CCX168, A Novel Small Molecule C5aR Antagonist for the Treatment of Inflammatory and Autoimmune Diseases
Date:1/28/2010

of 2010 for the treatment of type 2 diabetes mellitus, CCX354, a CCR1 antagonist in a Phase II clinical trial for the treatment of rheumatoid arthritis and CCX168, a C5aR antagonist, in Phase I clinical development. ChemoCentryx also has several programs in preclinical development. ChemoCentryx is privately held. For more information, please refer to www.chemocentryx.com.

Any statements in this press release about ChemoCentryx's expectations, beliefs, plans, objectives, assumptions or future events or performance are not historical facts and are forward-looking statements. These statements are often, but not always, made through the use of words or phrases such as may, believe, will, expect, anticipate, estimate, intend, predict, seek, potential, continue, plan, should, could and would or the negative of these terms or other comparable terminology. Forward-looking statements are not guarantees of performance. They involve known and unknown risks, uncertainties and assumptions that may cause actual results, levels of activity, performance or achievements to differ materially from any results, levels of activity, performance or achievements expressed or implied by any forward-looking statement. Some of the risks, uncertainties and assumptions that could cause actual results to differ materially from estimates or projections contained in the forward-looking statements include but are not limited to (i) the initiation, timing, progress and results of ChemoCentryx's preclinical studies and clinical trials, (ii) ChemoCentryx's ability to advance product candidates into clinical trials, (iii) GSK's exercise of its license options, (iv) the commercialization of ChemoCentryx's product candidates, (v) the implementation of ChemoCentryx's busin
'/>"/>

SOURCE ChemoCentryx, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. ChemoCentryx Initiates Clinical Trial of CCR1 Inhibitor CCX354
2. ChemoCentryx Completes Enrollment of PROTECT-1, a Phase II/III Clinical Trial of CCR9 Antagonist CCX282-B (Traficet-EN(TM)) in Crohns Disease
3. PROTECT-1 Phase II/III Induction-Stage Results for ChemoCentryxs Traficet-EN(TM) Presented in Oral Session at DDW 2009 Conference
4. ChemoCentryx Reports Additional New Data from the PROTECT-1 Study Demonstrating Traficet-ENs Effectiveness in Maintaining Remission in Patients with Crohns Disease
5. ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference
6. ChemoCentryx Initiates Phase 2 Clinical Trial of CCX354 for the Treatment of Rheumatoid Arthritis
7. Carrington Subsidiary DelSite Initiates Critical Toxicology Studies of Its Nasal Powder Bird Flu Vaccine
8. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
9. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
10. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
11. MedImmune Initiates Phase 2a Multi-Dose Study in Patients with Asthma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... 30, 2015  ResMed Inc. (NYSE: RMD ) ... 2015.  Revenue for the quarter was $453.1 million, a ... 30, 2014 (a 17 percent increase on a constant ... the quarter ended June 30, 2014.  Diluted earnings per ... quarter ended June 30, 2014.  The ...
(Date:7/30/2015)... July 30, 2015  EP Global Communications, Inc. (Public ... recently contacted the Company about discussing EPGL,s electronic ... as Monday, August 3, 2015.  Novartis CEO ... that the coming electronic contact lens market could ... the next several years.  Novartis partnered with Google ...
(Date:7/30/2015)... July 30, 2015  Unichem Pharmaceuticals ( USA ... of Hydrochlorothiazide tablets 25 mg 1000-count bottle to the ... precautionary measure due to the identification of a Clopidogrel ... The risk associated with mistakenly taking a ... increased probability of experiencing Clopidogrel,s side effects which include ...
Breaking Medicine Technology:ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 2ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 3ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 4ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 5ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 6ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 7ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 8ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 9ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 10ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 11ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 12ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 13ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 14ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 15ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 16Unichem Pharmaceuticals (USA), Inc. Issues a Voluntary Nationwide Recall of Hydrochlorothiazide Tablets Due to the Potential Presence of Foreign Tablets 2
... Ellman International, Inc., a New York based developer, manufacturer ... procedures, announced that Frank D. D,Amelio will join its ... (COO), Executive Vice President. "We are proud to welcome ... help guide the company,s continued growth," said Chief Executive ...
... This month, Minnesotans are recognized for their outstanding ... and for their donations of the blood component, plasma, ... Throughout September, Minnesota Gov. Tim Pawlenty is recognizing "Plasma ... to raise awareness for the rare, genetic diseases treated ...
Cached Medicine Technology:Ellman International Announces Executive Team Hire 2Minnesotans Help Produce As Well As Benefit from Lifesaving Therapies 2
(Date:7/31/2015)... ... July 31, 2015 , ... In the most recent ... Court in the Northern District of Illinois, Androgel testosterone attorneys report that a “Mini ... docket entry was made recording the minutes of the status conference, which was held ...
(Date:7/31/2015)... ... July 31, 2015 , ... People love to feel like ... where price is an important factor to clients when choosing to purchase a ... the Preferred Producer Multi-Life Discount program, where advisers pass savings onto their clients. ...
(Date:7/30/2015)... ... July 31, 2015 , ... Reduce Human Error on ... by FDAnews and Ginette M. Collazo, Inc.**, Sept. 16-17, 2015 – Raleigh, NC, ... drug, biologic and device firms reduce manufacturing errors by 50 percent or more, ...
(Date:7/30/2015)... ... 2015 , ... As more hospitals across the country see the value in ... challenge. Because of growing competition, it is more important than ever to market ... The team at Wound Care Advantage has found that while many hospitals ...
(Date:7/30/2015)... Miami, FL (PRWEB) , ... July 30, 2015 ... ... a new online program entitled " Lovetraction Lines ." It's for women interested ... in the men they desire. The course, which officially launched to the public ...
Breaking Medicine News(10 mins):Health News:Testosterone Lawsuit News: Androgel Lawsuit Conference Held 2Health News:Testosterone Lawsuit News: Androgel Lawsuit Conference Held 3Health News:Testosterone Lawsuit News: Androgel Lawsuit Conference Held 4Health News:Secura Consultants Gives Advisers Competitive New Edge with Multi-Life Discount Program 2Health News:FDAnews Announces — Reduce Human Error on the Drug and Device Manufacturing Floor: Reduce Errors By 50% or More Workshop, Sept. 16-17, 2015 2Health News:FDAnews Announces — Reduce Human Error on the Drug and Device Manufacturing Floor: Reduce Errors By 50% or More Workshop, Sept. 16-17, 2015 3Health News:FDAnews Announces — Reduce Human Error on the Drug and Device Manufacturing Floor: Reduce Errors By 50% or More Workshop, Sept. 16-17, 2015 4Health News:WCA Offers Shockwave; The Marketing Module for Hospital Wound Care Programs 2Health News:WCA Offers Shockwave; The Marketing Module for Hospital Wound Care Programs 3Health News:WCA Offers Shockwave; The Marketing Module for Hospital Wound Care Programs 4Health News:Lovetraction Lines - Review Examining Simone Myers' New Online Course Released 2
... real-time imaging and image guidance systems for use in,the operating room, will be holding its annual ... DATE: May ... 9:30 am, Eastern Daylight Time, LOCATION: ... 150 King Street West ...
... Using ... ImmunoCAP -, PORTAGE, Mich., May ... and Clinical Immunology revealed variations in,the results of three common allergy diagnostic ... specialists at,Mount Sinai School of Medicine, determined that the laboratory results from,two ...
... May 8 In March, AHIP,s Board of,Directors ... the,Medicare Advantage and Medicare Part D plan marketing ... issued its new regulations., (Logo: http://www.newscom.com/cgi-bin/prnh/20040830/AHIPLOGO ... to ensure beneficiaries can rely on the,information being ...
... prolongs the life of these growth-driving molecules in breast ... Emory University,s Winship Cancer Institute. , The results are ... journal Molecular Cell. , Most breast cancers contain estrogen ... of the hormone estrogen. Their presence can determine whether ...
... May 8, 2008 People with diagnosed diabetes are nearly ... by arthritis hinders the successful management of both diseases, according ... released today by the Centers for Disease Control and Prevention ... kind to look at the relationship between arthritis and diabetes ...
... Neuroscientists at Johns Hopkins have discovered that mice ... exhibit a number of schizophrenia-like behaviors. The finding ... in the development of schizophrenia and related psychiatric ... for developing therapies. , The BACE1 enzyme, ...
Cached Medicine News:Health News:Novadaq Technologies Notice of Annual Meeting 2Health News:Novadaq Technologies Notice of Annual Meeting 3Health News:Data Show Common Allergy Tests Are Not Interchangeable 2Health News:Data Show Common Allergy Tests Are Not Interchangeable 3Health News:Previously unseen switch regulates breast cancer response to estrogen 2Health News:New report: Arthritis is a potential barrier to physical activity for adults with diabetes 2Health News:Hopkins researchers discover new link to schizophrenia 2
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: